SCHEMBL4093948

SCHEMBL4093948

Nc1ncc(-c2ccc(Cl)c(N)c2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.50
NTRK1 P04629 1/20 0.47
DHFR P00374 1/20 0.46
PIK3CD O00329 3/20 0.46
TSHR P16473 2/20 0.45
TP53 P04637 1/20 0.45
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972528 0.82 TSHR (0.62) NTRK1PIK3CDTSHRTP53ALDH1A1
SCHEMBL30839800 0.82 TSHR (0.62) NTRK1PIK3CDTSHRTP53ALDH1A1
SCHEMBL31607615 0.82 TSHR (0.62) NTRK1PIK3CDTSHRTP53ALDH1A1
SCHEMBL25712305 0.81 MAP4K4 (0.47) MAP4K4DHFRPIK3CDTSHRALDH1A1
SCHEMBL1388741 0.77 DHFR (0.79) MAP4K4DHFRALDH1A1SMN1; SMN2NPC1
SCHEMBL9630036 0.76 AHR (0.70) DHFRTSHRTP53ALDH1A1CYP3A4
SCHEMBL4096354 0.74 DHFR (0.68) MAP4K4DHFRALDH1A1CYP3A4LMNA
SCHEMBL7160538 0.74 DHFR (0.56) NTRK1DHFRALDH1A1SMN1; SMN2NPC1
SCHEMBL3644593 0.74 DHFR (0.56) DHFRADORA1KMOALOX5APFEN1
SCHEMBL5321375 0.74 MAP4K4 (0.67) MAP4K4TP53ALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 MAP4K4 448/4885NTRK1 3954/4885DHFR 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.